Adial Pharmaceuticals is progressing its genetically targeted treatment AD04 for alcohol use disorder through adaptive Phase 3 trials focused on identified genetic subgroups. The latest 10-Q reveals a shrinking cash runway into the second half of 2026, underscoring urgent financing needs despite strategic collaborations, chiefly with Molteni Farmaceutici for European commercialization. The company's business model revolves around delivering a companion diagnostic-enabled therapeutic with patent protection into a competitive addiction treatment landscape. Key near-term catalysts include regulatory alignment efforts, execution of definitive commercial agreements, and potential FDA priority voucher outcomes. Funding challenges and clinical development uncertainties remain pronounced risks to watch.